Feature

Stopping anti-TNF drugs in PsA has high rebound risk

Publish date: October 26, 2017

 

FROM JOURNAL OF RHEUMATOLOGY

Pages

Recommended Reading

Launch of adalimumab biosimilar Amjevita postponed
Psoriatic Arthritis ICYMI
TNF inhibitors associated with fewer side effects than methotrexate in children with psoriasis
Psoriatic Arthritis ICYMI
Ixekizumab has profound impact on genital psoriasis
Psoriatic Arthritis ICYMI
Genital psoriasis is the worst: Patients sound off
Psoriatic Arthritis ICYMI
Biologic approved for moderate to severe psoriasis in adolescents
Psoriatic Arthritis ICYMI
Pediatric psoriasis carries sharply increased risk of selected autoimmune comorbidities
Psoriatic Arthritis ICYMI
High ‘nocebo’ effect observed when patients knowingly switch to a biosimilar
Psoriatic Arthritis ICYMI
Psoriasis: Biologics bring potential for long-term remission off treatment
Psoriatic Arthritis ICYMI
Golimumab earns new FDA approvals
Psoriatic Arthritis ICYMI
Biosimilars poised to save $54 billion over the next decade
Psoriatic Arthritis ICYMI

Related Articles